Search
- Do patients with a non-invasive type of #BreastCancer need surgery to prevent progression—or is it better to hold off & carefully monitor their condition? A @ucsfcancer.bsky.social clinical trial focuses on determining the best approach for patients with #DCIS. ucsfh.org/4ryI13X
- Remembering Dr. Maryam Mirzakhani on #WorldCancerDay. Dr. Mirzakhani was first woman to win the Fields Medal, the most prestigious award in #mathematics. She died in 2017 from #breastcancer at the age of 40. stanford.io/2C0io2A #WomenInSTEM
- Die DSMZ stellt nicht nur genau charakterisierte Brustkrebs-Zelllinien für Forschungsteams weltweit bereit. Mit diesen Zelllinien lassen sich bessere Modelle für neue Therapien entwickeln und bestehende Behandlungen verbessern. 👉 tinyurl.com/yekh2um4 #BreastCancer #CancerResearch #OpenData
- A new drug for hard-to-treat #BreastCancer 💊 Samuraciclib, discovered at @imperialcollegeldn.bsky.social, helped shrink tumours in over half of patients in a Phase 2 trial for advanced breast cancer – and is now heading to Phase 3. www.imperial.ac.uk/news/article... 5/6
- Four years today they amputated my cancerous breasts. This marks my 4th year of NED (no evidence of disease). One more year without recurrence and I'll officially be in remission. #cancersky #breastcancer #cancer #NED #HER2+
- We invite you to join us for #GrandRounds today at 12pm as Dr. Gaorav Gupta @guptalabunc.bsky.social presents "Immunogenicity of DNA damage in #breastcancer prevention and therapy." Please join us in Smilow Auditorium or via Zoom: bit.ly/4qy6JRf.
- Epigenetics Update - EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity bit.ly/4qOfmYw William J Muller (McGill University) reporting in EMBO Rep #Epigenetics #EZH2 #BreastCancer --- Perfect for cancer, immunology, and aging research; epigenometech.com
- The PREDICT breast web tool is now fifteen years old. breast.v3.predict.cam It is free to use. The tool has been used over 4 million times. If you'd like to sponsor the costs of web site maintenance or ongoing development send me a DM. #breastcancer
- Proud to have contributed to this paper, looking at real world evidence on the efficacy and safety of pembrolizumab in patients with early triple negative #BreastCancer www.sciencedirect.com/science/arti...
- We are looking forward to attending UKIBCS this morning and learning about recent advances in #BreastCancer 🧪
- Read more about our #BreastCancer blood test research, funded by @breastcancernow.bsky.social and @nihr.bsky.social, in @andrewgregory.com's article in @theguardian.com ⤵️ www.theguardian.com/science/2026...
- 📰NEWS: A simple blood test can predict how well patients with #BreastCancer will respond to targeted therapies – before treatment begins. Read more in our 🧵 ⤵️
- Researchers at @UCSDMedSchool.bsky.social and @UCSDCancer are uncovering new vulnerabilities in the most aggressive #breastcancer. Findings could result in new, more effective treatments. #cancerresearch #cancer #research @AACR buff.ly/I6yjtyp
- A drug used to treat hot flushes could also slow #breastcancer, says a team @crukcamcentre.bsky.social 💊 A Cambridge-led trial shows a progesterone-like treatment eases symptoms and has anti-cancer activity. Read more about the study 👇 bit.ly/49cXCzZ
- While nutrition + exercise was shown to improve QoL post-treatment for #breastcancer, a recent study led by Leah Puklin, MPH, found nutrition + exercise had no impact on treatment-related declines during chemotherapy. academic.oup.com/jncics/advan...
- From risk to survivorship, explore key clinical considerations in #breastcancer care at our free networking and #CME dinner, Wed., Jan. 28 at 6pm in Westerly, RI. Presenters: Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski + @maryamlustberg.bsky.social. ➡️RSVP: bit.ly/48QFOcc
- 📣 New from Balla et al! 📄 Understanding Exceptional Response: The Role of MINDY1 SNP in CDK4/6 Inhibitor Therapy for ER-Positive, HER2-Negative Advanced #breastcancer 👉 bit.ly/4qy78TZ
- Nassar et al’s study demonstrates high concordance of Recurrence Score® (RS) results between paired core needle biopsy (CNB) and surgical excision (SE) samples, which supports use of CNB for Oncotype DX® testing. Read the full article. ascopubs.org/doi/abs/10.1... #BreastCancer #bcsm
- Join us Wednesday, Jan. 28 at 6pm for a free networking and #CME dinner on women's health + #breastcancer. Presenters include Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski, and @maryamlustberg.bsky.social. ➡️RSVP bit.ly/48QFOcc
- Tonight on #YaleCancerAnswers, Dr. Daniel O'Neil discusses the latest research on improving #breastcancer outcomes in low-middle income countries. 🔸Listen live on WNPR 🔸Download via Apple Podcasts 🔸Watch on YouTube
- The #WISDOM study looked at risk-based screening for #breastcancer + results were presented at #SABCS25. Dr. Eric Winer: "It is practice-changing, and I think it has huge public health implications.” ➡️ www.nytimes.com/2025/12/12/h...
- New research from #SABCS25 suggests acupuncture may help ease “chemo brain.” 🎧 Hear Dr. Jun Mao of @mskcancercenter.bsky.social explain more about the results of his research on our podcast today: bit.ly/4pE6TH1 #BreastCancer #Breastcancerresearch
- Simultaneous publication at #SABCS25! Horimoto et al.'s real-world data explores the clinical relevance of HER2 mutations in the efficacy of Trastuzumab Deruxtecan for HER2-low metastatic breast cancer. 👉 See the analysis: ascopubs.org/doi/abs/10.1... #BreastCancer
- 🚨 HER2+ MBC Maintenance News! 🚨 The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance. 👉 See the results: ascopubs.org/doi/abs/10.1... #HER2Positive #BreastCancer
- Results from #SABCS25: A trial, reported by breast cancer medical oncologist @breastcancerdoc.bsky.social, show that a new treatment continues to be effective at stopping advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy. bit.ly/3MGgZs6
- New data may reshape early-stage Triple-Negative Breast Cancer (TNBC) care! Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane. 👉 Read the results: ascopubs.org/doi/abs/10.1... #TNBC #BreastCancer
- Dr. Jun Mao, the Integrative Medicine and Wellness Service Chief at MSK, presented research on the benefits of acupuncture for #breastcancer patients who experience cancer-related cognitive impairment at the 2025 @sabcs.bsky.social . Learn more: bit.ly/4aeZAkg
- #SABCS25 posters! Visit Dr. Tiffany Traina to learn about the safety analysis of first-line datopotamab deruxtecan vs chemo for locally recurrent inoperable or metastatic triple negative #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social ⏰ 12:30–2 p.m. CST bit.ly/4puGBqn
- #Giredestrant oral SERD ➡️ incredible 30% benefit for those with early stage ER+ #breastcancer. It's not on the market yet but other similar #bcsm 💊 cost >$20k/mo vs generic AI $7.50 (on CPD w/o insurance). Let's see some affordable pricing please.🙏 #SABCS25 #financialToxicity
- TODAY at the #SABCS25: Dr. Jun Mao, an integrative medicine specialist at MSK, will present research on the effects of acupuncture versus sham acupuncture and usual care on cancer-related cognitive difficulties among #breastcancer survivors. @sabcs.bsky.social 🗓️: December 12 at 9 a.m. (CST)
- De. Adam Krysztofiak shares how HER2-targeted triplex-forming oligonucleotides (TFOs) cause DNA damage + trigger cell death in HER2+ #breastcancer cells. They turn on the immune system, offering a new way to improve responses + overcome resistance to HER2 therapies. #sabcs @oncoalert.bsky.social
